Ranking the contribution of behavioral measures comprising oxycodone self-administration to reinstatement of drug-seeking in male and female rats.

escalation female front-loading opioid relapse sex difference vulnerability

Journal

Frontiers in behavioral neuroscience
ISSN: 1662-5153
Titre abrégé: Front Behav Neurosci
Pays: Switzerland
ID NLM: 101477952

Informations de publication

Date de publication:
2022
Historique:
received: 02 09 2022
accepted: 04 11 2022
entrez: 12 12 2022
pubmed: 13 12 2022
medline: 13 12 2022
Statut: epublish

Résumé

Rates of relapse to drug use during abstinence are among the highest for opioid use disorder (OUD). In preclinical studies, reinstatement to drug-seeking has been extensively studied as a model of relapse-but the work has been primarily in males. We asked whether biological sex contributes to behaviors comprising self-administration of the prescription opioid oxycodone in rats, and we calculated the relative contribution of these behavioral measures to reinstatement in male and female rats. Rats were trained to self-administer oxycodone (8 days, training phase), after which we examined oxycodone self-administration behaviors for an additional 14 days under three conditions in male and female rats: short access (ShA, 1 h/d), long access (LgA, 6 h/d), and saline self-administration. All rats were then tested for cue-induced reinstatement of drug-seeking after a 14-d forced abstinence period. We quantified the # of infusions, front-loading of drug intake, non-reinforced lever pressing, inter-infusion intervals, escalation of intake, and reinstatement responding on the active lever. Both male and female rats in LgA and ShA conditions escalated oxycodone intake to a similar extent. However, males had higher levels of non-reinforced responding than females under LgA conditions, and females had greater levels of reinstatement responding than males. We then correlated each addiction-related measure listed above with reinstatement responding in males and females and ranked their respective relative contributions. Although the majority of behavioral measures associated with oxycodone self-administration did not show sex differences on their own, when analyzed together using partial least squares regression, their relative contributions to reinstatement were sex-dependent. Front-loading behavior was calculated to have the highest relative contribution to reinstatement in both sexes, with long and short inter-infusion intervals having the second greatest contribution in females and males, respectively. Our results demonstrate sex differences in some oxycodone self-administration measures. More importantly, we demonstrate that a sex- dependent constellation of self-administration behaviors can predict the magnitude of reinstatement, which holds great promise for relapse prevention in people.

Identifiants

pubmed: 36505730
doi: 10.3389/fnbeh.2022.1035350
pmc: PMC9731098
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1035350

Subventions

Organisme : NIDA NIH HHS
ID : K00 DA053527
Pays : United States

Informations de copyright

Copyright © 2022 Guha, Alonso-Caraballo, Driscoll, Babb, Neal, Constantino, Lintz, Kinard and Chartoff.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Am J Psychiatry. 2005 Aug;162(8):1423-31
pubmed: 16055763
Biol Psychiatry. 2019 Dec 1;86(11):848-856
pubmed: 31326085
Horm Behav. 2010 Jun;58(1):44-56
pubmed: 19818789
Science. 1998 Oct 9;282(5387):298-300
pubmed: 9765157
Science. 2004 Aug 13;305(5686):1014-7
pubmed: 15310906
Psychopharmacology (Berl). 2017 Mar;234(6):977-987
pubmed: 28127624
Psychopharmacology (Berl). 2001 Jun;156(1):98-107
pubmed: 11465640
Nat Protoc. 2007;2(11):2987-95
pubmed: 18007634
Psychol Rev. 1987 Oct;94(4):469-92
pubmed: 3317472
Psychopharmacology (Berl). 2021 Apr;238(4):1029-1046
pubmed: 33404740
Pharmacol Rev. 2016 Apr;68(2):242-63
pubmed: 26772794
J Neurosci. 2012 Aug 22;32(34):11600-9
pubmed: 22915104
Pharmacol Rev. 2002 Mar;54(1):1-42
pubmed: 11870259
Addict Biol. 2021 May;26(3):e12973
pubmed: 33078503
Physiol Behav. 2015 May 1;143:58-69
pubmed: 25708277
Neuropsychopharmacology. 2020 Jul;45(8):1251-1262
pubmed: 31747681
Annu Rev Neurosci. 1995;18:463-95
pubmed: 7605071
Front Neuroendocrinol. 2014 Jan;35(1):111-39
pubmed: 24287074
J Neurosci. 2016 May 25;36(21):5748-62
pubmed: 27225765
Clin Psychol Rev. 2018 Dec;66:12-23
pubmed: 29174306
Int J Neuropsychopharmacol. 2019 Jun 3;22(6):383-393
pubmed: 30989210
Neuropsychopharmacology. 2014 Jan;39(2):254-62
pubmed: 24121188
Psychopharmacology (Berl). 2009 May;203(4):677-84
pubmed: 19043694
Behav Pharmacol. 1999 Sep;10(5):513-21
pubmed: 10780257
Neuropharmacology. 2019 Jun;151:189-194
pubmed: 30880124
Pharmacol Res. 2019 Jan;139:158-165
pubmed: 30465850
Neuropsychopharmacology. 2022 Jun;47(7):1285-1291
pubmed: 35338255
J Clin Psychol. 1971 Oct;27(4):455-6
pubmed: 5115648
Neuropsychopharmacology. 2017 Apr;42(5):1126-1135
pubmed: 28025975
Neuropsychopharmacology. 2020 Apr;45(5):770-779
pubmed: 31905372
Addiction. 2001 Jan;96(1):103-14
pubmed: 11177523
Pharmacol Biochem Behav. 1989 Feb;32(2):527-31
pubmed: 2727015
J Neurosci. 2006 Jun 14;26(24):6450-7
pubmed: 16775132
Psychopharmacology (Berl). 2005 Jul;180(3):473-90
pubmed: 15731896
Psychopharmacology (Berl). 2010 Jun;210(2):241-52
pubmed: 20372879
Neuropsychopharmacology. 2019 Feb;44(3):465-477
pubmed: 30293087
Neuropsychopharmacology. 2000 Apr;22(4):413-21
pubmed: 10700660
Prog Brain Res. 2016;224:25-52
pubmed: 26822352
J Neurosci. 2013 Dec 4;33(49):19384-92
pubmed: 24305833
Biol Psychiatry. 2016 Jan 1;79(1):39-46
pubmed: 25747744
Br J Pharmacol. 2022 Jan;179(2):227-241
pubmed: 34505281
Biol Psychiatry. 2020 Jan 1;87(1):44-53
pubmed: 31400808
Neuropsychopharmacology. 2019 Jan;44(1):166-183
pubmed: 29946108
Psychopharmacology (Berl). 2020 Nov;237(11):3369-3381
pubmed: 32990768
Biol Psychiatry. 2009 May 15;65(10):863-8
pubmed: 18639867
Front Pharmacol. 2014 May 27;5:116
pubmed: 24904419

Auteurs

Suman K Guha (SK)

Basic Neuroscience Division, McLean Hospital, Department of Psychiatry, Harvard Medical School, Belmont, MA, United States.

Yanaira Alonso-Caraballo (Y)

Basic Neuroscience Division, McLean Hospital, Department of Psychiatry, Harvard Medical School, Belmont, MA, United States.

Gillian S Driscoll (GS)

Basic Neuroscience Division, McLean Hospital, Department of Psychiatry, Harvard Medical School, Belmont, MA, United States.

Jessica A Babb (JA)

Research Service, VA Boston Healthcare System, Department of Psychiatry, Harvard Medical School, Boston, MA, United States.

Megan Neal (M)

Basic Neuroscience Division, McLean Hospital, Department of Psychiatry, Harvard Medical School, Belmont, MA, United States.

Nicholas J Constantino (NJ)

Basic Neuroscience Division, McLean Hospital, Department of Psychiatry, Harvard Medical School, Belmont, MA, United States.

Tania Lintz (T)

Basic Neuroscience Division, McLean Hospital, Department of Psychiatry, Harvard Medical School, Belmont, MA, United States.

Elizabeth Kinard (E)

Basic Neuroscience Division, McLean Hospital, Department of Psychiatry, Harvard Medical School, Belmont, MA, United States.

Elena H Chartoff (EH)

Basic Neuroscience Division, McLean Hospital, Department of Psychiatry, Harvard Medical School, Belmont, MA, United States.

Classifications MeSH